The effect of aspirin withdrawal time on the recovery of patient underwent transurethral resection of prostate

doi:10.3877/cma.j.issn.1674-3253.2018.02.003

Abstract

Abstract:

Objective

To summarize the effects of aspirin withdrawal time on the recovery of patient underwent transurethral resection of prostate (TURP).

Methods

The clinical data of BPH patients underwent TURP in our department between 2010 and 2015 were reviewed. According to the patients whether taken Asprin and the Asprin withdrawal time, these patients were divided into three groups: group 1, stop Asprin during perioperative period for 7 days; group 2, stop Asprin during perioperative period more than 7 days; control group, not taken Asprin. The volume of prostate, operating time, intraoperative bleeding amount, the length of hospital stay, the length of hospital stay after operation, the case of blood transfusion, hemoglobin decline in the first day after operation, the weight of resected prostate, the time of bladder irrigation and catheter removed after surgery, and the complication of cardio-cerebral vascular in perioperative period were compared.

Results

There were no significant differences in operation time, intraoperative bleeding amount, hemoglobin decline, the time of bladder irrigation, the time of catheter removed, and the length of hospital stay between the three groups (P>0.05). No severe cardio-cerebral vascular events occurred in all patients during the perioperative period.

Conclusion

Stop taking Asprin before TURP operation for 7 days is effective to reduce the bleeding and cardio-cerebral vascular complications.

Key words: Benign prostatic hyperplasia, Transurethral resection of prostate, Aspirin

Jiahui Zhao, Zhu Hou, Yong Luo, Mingchuan Li, tao Peng, Yongxing Wang, Yongguang Jiang. The effect of aspirin withdrawal time on the recovery of patient underwent transurethral resection of prostate[J]. Chinese Journal of Endourology(Electronic Edition), 2018, 12(02): 79-82.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2018.02.003

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2018/V12/I02/79

Figures/Tables 1

References 15

[1]	Jun JEJ, Kinkade A, Tung ACH, et al. 5alpha-reductase lnhibitors for treatment of benign prostatic hyperplasia: a systematic review and meta-analysis[J]. Can J Hosp Pharm, 2017, 70(2): 113-119.
[2]	刘和谦, 陈弋生, 邹滨, 等. 前列腺体积对经尿道前列腺电切术治疗效果的影响[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2017, 11(1): 58-61.
[3]	Zhao M, Klipstein-Grobusch K, Wang X, et al. Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysis[J]. PLoS One, 2017, 12(4): e0175947.
[4]	Banerjee S, Angiolillo DJ, Boden WE, et al. Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery[J]. J Am Coll Cardiol, 2017, 69(14): 1861-1870.
[5]	Song JW, Soh S, Shim JK. Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications[J]. Korean J Anesthesiol, 2017, 70(1): 13-21.
[6]	Godschalk TC, Willemsen LM, Zwart B, et al. Effect of tailored antiplatelet therapy to reduce recurrent stent thrombosis and cardiac death after a first episode of stent thrombosis[J]. Am J Cardiol, 2017, 119(10): 1500-1506.
[7]	Alkhail BA, Iftikhar R, Shaikh AA. Use of Aspirin and Statin as primary prevention for cardiovascular diseases[J]. Pak J Med Sci, 2016, 32(6): 1336-1339.
[8]	LaBresh KA, Ellrodt AG, Gliklich R, et al. Get with the guidelines for cardiovascular secondary prevention: pilot results[J]. Arch Intern Med, 2004, 164(2): 203-209.
[9]	Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease[J]. Eur Heart J, 2006, 27(22): 2667-2674.
[10]	Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis[J]. J Intern Med, 2005, 257(5): 399-414.
[11]	Taylor K, Filgate R, Guo DY, et al. A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs[J]. BJU Int, 2011, 108 Suppl 2: 45-50.
[12]	Nielsen JD, Holm-Nielsen A, Jespersen J, et al. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy--a prospective, randomized, double-blind, placebo-controlled study[J]. Scand J Urol Nephrol, 2000, 34(3): 194-198.
[13]	Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial[J]. Br J Anaesth, 2010, 104(3): 305-312.
[14]	Enver MK, Hoh I, Chinegwundoh FI. The management of aspirin in transurethral prostatectomy: current practice in the UK[J]. Ann R Coll Surg Engl, 2006, 88(3): 280-283.
[15]	赵佳晖, 姜永光, 侯铸, 等. 经尿道前列腺电切术治疗合并冠脉支架的前列腺增生患者的临床经验[J/CD]. 中华腔镜泌尿外科杂志(电子版). 2017, 11(2): 101-104.

组别	例数	年龄（岁，±s）	前列腺体积（ml，±s）	高血压（例）	冠心病（例）	糖尿病（例）	手术时间（min，±s）	切除前列腺重量（g，±s）
对照组	37	72±7	54±26	15	04^*	07	85±26	19±33
停药7 d组	40	71±6	60±29	27	34^*	12	88±28	20±21
停药>7 d组	42	72±7	55±27	24	28^*	12	84±31	21±25
统计值	-	F=0.385	F=0.581	χ²=5.730	χ²=46.12	χ²=1.439	F=0.245	F=0.052
P值	-	0.681	0.56	0.057	<0.01	0.487	0.783	0.949
组别	术中出血（ml，±s）	血红蛋白下降（g，±s）	住院时间（d，±s）	术后住院时间（±s）	冲洗时间（d，±s）	拔尿管时间（d，±s）
对照组	099±57	16±12	14±4	8.9±2.7	1.7±1.5	6.6±2.2
停药7 d组	120±61	16±17	15±5	9.5±4.6	2.1±2.0	7.6±4.3
停药>7 d组	124±53	15±15	21±5^＃	8.8±2.5	1.5±0.6	6.6±1.5
F值	2.059	0.053	24.046	0.566	1.707	1.412
P值	0.132	0.949	<0.01	0.569	0.186	0.248

组别	例数	年龄（岁，±s）	前列腺体积（ml，±s）	高血压（例）	冠心病（例）	糖尿病（例）	手术时间（min，±s）	切除前列腺重量（g，±s）
对照组	37	72±7	54±26	15	04^*	07	85±26	19±33
停药7 d组	40	71±6	60±29	27	34^*	12	88±28	20±21
停药>7 d组	42	72±7	55±27	24	28^*	12	84±31	21±25
统计值	-	F=0.385	F=0.581	χ²=5.730	χ²=46.12	χ²=1.439	F=0.245	F=0.052
P值	-	0.681	0.56	0.057	<0.01	0.487	0.783	0.949
组别	术中出血（ml，±s）	血红蛋白下降（g，±s）	住院时间（d，±s）	术后住院时间（±s）	冲洗时间（d，±s）	拔尿管时间（d，±s）
对照组	099±57	16±12	14±4	8.9±2.7	1.7±1.5	6.6±2.2
停药7 d组	120±61	16±17	15±5	9.5±4.6	2.1±2.0	7.6±4.3
停药>7 d组	124±53	15±15	21±5^＃	8.8±2.5	1.5±0.6	6.6±1.5
F值	2.059	0.053	24.046	0.566	1.707	1.412
P值	0.132	0.949	<0.01	0.569	0.186	0.248

Please choose a citation manager

Content to export